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Certain phthalates and bisphenol A (BPA) have been associated with insulin resistance 
and type 2 diabetes in non-pregnant adults, but studies of gestational diabetes mellitus 
(GDM) have reported conflicting results for phthalates and no associations with BPA. 
Our aim was to investigate the relationship between maternal serum levels of phthalate 
metabolites and phenols at 10–17  weeks of gestation and glucose homeostasis at 
28 weeks of gestation. 232 women aged ≥16 years without type 1 or 2 diabetes with sin-
gleton male pregnancies were recruited from a single UK maternity centre between 2001 
and 2009 as part of a prospective observational study (Cambridge Baby Growth Study). 
Serum levels of 16 phthalate metabolites and 9 phenols (including BPA) were measured 
using liquid chromatography/tandem mass spectrometry. Oral glucose tolerance tests 
were performed at 28 weeks. 47/232 (20.3%) women had GDM. First-trimester triclosan 
(TCS) was inversely associated with incident GDM (adjusted odds ratio per log increase 
in concentration 0.54, 95% confidence interval 0.34–0.86, p = 0.010). Amongst women 
without GDM, first-trimester mono-(2-ethylhexyl) phthalate and mono(carboxyisooctyl) 
phthalate levels were positively associated with 120-min plasma glucose (adjusted 
β 0.268 and 0.183, p = 0.0002 and 0.010, respectively) in mid-pregnancy. No other 
monotonic associations were detected between phthalate or phenol levels and fasting 
or stimulated plasma glucose, β-cell function, insulin resistance, or 60-min disposition 
index. Our results support a glycaemia-raising effect of phthalates during pregnancy, 
consistent with findings in non-pregnant populations and suggest a possible protective 
effect of exposure to TCS against GDM.
Keywords: gestational diabetes, pregnancy, phthalates, bisphenol a, triclosan, endocrine disrupting chemicals, 
environmental chemicals
Abbreviations: BP-3, benzophenone-3; BPA, bisphenol A; CBGS, Cambridge Baby Growth Study; DEHP, di-(2-ethylhexyl) 
phthalate; EDC, endocrine disrupting chemical; GDM, gestational diabetes mellitus; HOMA2, updated homeostasis model 
assessment; IGT, impaired glucose tolerance; IMD, Index of Multiple Deprivation 2007; LOD, limit of detection; MBzP, 
monobenzyl phthalate; MCiOP, mono(carboxyisooctyl) phthalate; MECPP, mono-(2-ethyl-5-carboxypentyl) phthalate; 
MEHP, mono-(2-ethylhexyl) phthalate; MEP, monoethyl phthalate; MiBP, monoisobutyl phthalate; MnBP, mono-n-butyl 
phthalate; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes mellitus.
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inTrODUcTiOn
Late pregnancy is characterised by peripheral insulin resist-
ance with a compensatory increase in insulin secretion and 
β-cell mass. Inadequacy of this response leads to gestational 
diabetes mellitus (GDM), which is associated with both peri-
natal and long-term adverse outcomes (1). The incidence of 
GDM in developed countries has increased significantly in 
recent years, a trend that cannot be fully explained by rising 
levels of maternal obesity (2). There is increasing interest in 
a possible role for endocrine disrupting chemicals (EDCs), 
exogenous substances that interfere with the endocrine sys-
tem and cause adverse health effects. Two groups of EDCs 
that have been well studied in the context of glycaemia are 
phthalic acid esters (phthalates) and bisphenol A (BPA, 
4,4′-dihydroxy-2,2-diphenylpropane).
Phthalates are ubiquitous industrial chemicals, several meta -
bolites of which are detectable in the urine of >75% of the general 
population (3). In vitro, phthalates activate peroxisome prolifera-
tor-activated receptors, which regulate cellular lipid and glucose 
metabolism (4), and reduce insulin receptor concentration (5). 
In rodents, phthalates impair insulin secretion and glucose toler-
ance (6). Epidemiological studies in non-pregnant adults have 
demonstrated associations between phthalates and raised fast-
ing blood glucose, insulin resistance, reduced insulin secretion, 
and type 2 diabetes mellitus (T2DM) (7–9). To date, only three 
epidemiological studies have assessed the associations between 
phthalates and gestational glycaemia. In a cohort of 72 women, 
first-trimester urinary concentrations of monoisobutyl phthalate 
(MiBP) and monobenzyl phthalate (MBzP) were inversely asso-
ciated with 60-min blood glucose levels measured 3–25 weeks later 
(10). In a larger study (n = 350), second-trimester urinary monoe-
thyl phthalate (MEP) was positively associated with impaired 
glucose tolerance (IGT), whereas di-(2-ethylhexyl) phthalate 
(DEHP) metabolites were associated with lower odds of IGT (11). 
The largest study (n = 1,274) observed no significant associations 
between first-trimester urinary phthalate metabolites and incident 
IGT/GDM (12).
Bisphenol A is another commonly used industrial chemical, 
detectable in the urine of 93% of the US population (13). It exerts 
oestrogenic and various other effects (7). In rodents, BPA causes 
disrupted insulin signalling, insulin resistance, and IGT (14). 
Epidemiological studies in non-pregnant adults have generated 
conflicting results for associations between BPA and insulin 
resistance and T2DM (9, 15–17). In the three studies of pregnant 
women to date, only one prospective cohort study (n =  245) 
reported a positive association between second-trimester (but not 
first-trimester) urinary BPA levels and stimulated blood glucose 
levels (but not incident GDM) at 24–28 weeks of gestation (18). 
In a larger study (n = 1,274), first-trimester urinary BPA was not 
significantly associated with incident IGT/GDM (12), and in a 
small case-control study (n = 94), second-trimester urinary BPA 
was not associated with GDM or fasting blood glucose levels 
amongst controls (19).
Other phenol compounds [4-tert-octyl phenol, benzophe-
none-3 (BP-3), and triclosan (TCS)] have not been associated 
with T2DM or fasting serum glucose in humans (20).
Our objective was to investigate the prospective relationships 
between maternal serum levels of phthalate metabolites, BPA, 
and other phenols at 10–17  weeks of gestation and glucose 
homeostasis at 28 weeks of gestation in a UK setting.
MaTerials anD MeThODs
study Design
Pregnant women aged ≥16 years (n = 2,229) were recruited to 
the Cambridge Baby Growth Study (CBGS), a large prospective 
cohort study, from routine antenatal clinics at 10–17  weeks of 
gestation at the Rosie Maternity Unit, Cambridge, between April 
2001 and March 2009. Characteristics of CBGS participants have 
previously been described (21). Written informed consent was 
obtained from all women.
A subcohort of 330 mothers of 334 male infants was selected 
for a nested case-control study of EDCs and cryptorchidism 
(30 infants with congenital cryptorchidism, 21 infants with 
postnatally acquired cryptorchidism, 285 controls). Of these, 
women were retrospectively included in the present study if they 
had a singleton pregnancy, no pre-existing diagnosis of type 1 
or 2 diabetes mellitus or GDM, and undertook an oral glucose 
tolerance test (OGTT) at 28  weeks of gestation. This subset of 
232 women was representative of the whole cohort with regard 
to age, ethnicity, pre-pregnancy body mass index (BMI), and 
deprivation index (all p > 0.2).
Non-fasting maternal serum samples were collected into 
plastic-free glass tubes at enrolment for measurement of 16 
phthalate metabolites and 9 phenols (Table  1). Serum samples 
were stored at −70°C. OGTTs were performed to diagnose GDM 
and assess β-cell function and insulin resistance.
Maternal Demographic characteristics
A questionnaire administered at ~36  weeks of gestation col-
lected demographic information, including history of diabetes 
mellitus, ethnicity, smoking, and parity. The Index of Multiple 
Deprivation 2007 (IMD), which measures various economic, 
social, and housing parameters, was derived from residential 
postcodes (22). The sample mean IMD value (9.37) was imputed 
for those cases where it was missing (n = 54) as these women 
did not differ from others with regard to age, pre-pregnancy 
BMI, ethnicity, smoking status, parity, or prevalence of GDM 
(all p > 0.3).
Oral glucose Tolerance Testing
At 28 weeks of gestation, a 75-g OGTT was performed follow-
ing an overnight fast. Venous whole blood glucose levels were 
measured at 0 and 60 min, and capillary blood glucose levels were 
measured at 0, 60, and 120 min. From May 2007 onwards, venous 
whole blood glucose levels were also measured at 120  min (in 
56/232 women, 24.1%). Women completing OGTTs before May 
2007 did not differ from those completing OGTTs during/after 
May 2007 with regard to age, BMI, IMD, ethnicity, smoking status, 
parity, or prevalence of GDM (all p > 0.1). Insulin and C-peptide 
levels were measured at 0 and 60 min in 158/232 (68.1%) women. 
Women with missing insulin and C-peptide levels did not differ 
Table 1 | Medians, quartiles, and ranges of serum concentrations of the investigated phthalate metabolites and phenols in the study population (n = 232 for 
phthalates, n = 228 for phenols).
chemical concentration (μg/l)a limit of detection 
(lOD)
Detection 
rate (%)
Minimum Percentiles Maximum
25th 50th 75th
Phthalate metabolites [parent compound]
Monoethyl phthalate (MEP) [DEP]b 0.50 90.5 <LOD 0.79 1.56 4.26 172.05
Monoisobutyl phthalate (MiBP) [DiBP]b 0.77 97.8 <LOD 1.97 3.78 6.60 29.34
Mono-n-butyl phthalate (MnBP) [DnBP]b 0.82 71.6 <LOD 1.34 2.31 9.41
Mono-pentyl phthalate (MPP) [DPP]b 0.20 0.4 <LOD 0.24
Monobenzyl phthalate (MBzP) [BBzP]b 0.40 6.9 <LOD 1.08
Mono-(2-ethylhexyl) phthalate (MEHP) [DEHP]b 0.60 63.8 <LOD 1.14 58.53 421.93
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) [DEHP] 0.56 6.9 <LOD 4.45
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) [DEHP] 0.35 2.3 <LOD 1.94
Mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP) [DEHP] 0.28 79.3 <LOD 0.30 0.52 0.95 14.39
Mono-n-octyl phthalate (MOP) [DnOP]b 0.20 0.4 <LOD 0.26
Mono-(3-carboxypropyl) phthalate (MCPP) [DnOP] 0.36 0.4 <LOD 0.44
Mono-isononyl phthalate (MiNP) [DiNP]b 0.20 19.0 <LOD 3.24
Mono(hydroxyisononyl) phthalate (MHiNP) [DiNP] 0.38 0.0 <LOD
Mono-oxoisononyl phthalate (MOiNP) [DiNP] 0.10 3.4 <LOD 0.22
Mono(carboxyisooctyl) phthalate (MCiOP) [DiNP] 0.10 75.4 <LOD 0.10 0.18 0.37 13.76
Mono-isodecyl phthalate (MiDP) [DiDP]b 0.20 3.4 <LOD 0.43
Phenols
Bisphenol A (BPA) 0.18 89.9 <LOD 1.02 1.76 2.96 8.46
Triclosan (TCS) 0.22 69.3 <LOD 0.93 8.29 178.75
Triclocarban (TCC) 0.27 26.3 <LOD 0.36 18.85
Benzophenone-3 (BP-3) 0.12 70.2 <LOD 0.34 0.79 67.11
2,4-dichlorophenol (2,4-DCP) 0.18 11.4 <LOD 0.69
2,5-dichlorophenol (2,5-DCP) 0.11 4.5 <LOD 3.88
2,4,5-trichlorophenol (2,4,5-TCP) 0.29 0.4 <LOD 1.26
2-phenylphenol (2-PP) 0.13 41.2 <LOD 0.23 0.74
4-phenylphenol (4-PP) 0.12 5.7 <LOD 0.37
a<LOD: below the LOD.
bSemiquantitative data (see Materials and Methods).
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from others with regard to age, BMI, IMD, ethnicity, smoking 
status, parity, or prevalence of GDM (all p > 0.1). Glycated hae-
moglobin levels were not measured.
assays
We measured phthalate metabolites rather than their diester 
parent compounds, as the latter are metabolised rapidly (23), 
and exposure misclassification could potentially occur from 
contamination of the samples with phthalate diesters during ven-
esection or laboratory handling. Serum samples were analysed 
for the total content of 16 phthalate metabolites (from 9 parent 
phthalate diesters) and 9 phenols (Table  1) by isotope-diluted 
liquid chromatography coupled to tandem mass spectrom-
etry. The method and determination of the limit of detection 
(LOD) was as previously described (24, 25) (Supplementary 
Methods in Supplementary Material). Measured levels of the 
phthalate monoesters were considered to be semiquantita tive, 
as hydrolysis of potentially contaminating diester phthalates 
to monoester phthalates [e.g., DEHP to mono-(2-ethylhexyl) 
phthalate (MEHP)] by enzymes present in blood may have 
occurred after the samples were drawn. However, the large inter-
individual variation observed for these metabolites suggests that 
a systematic contamination of the samples with one or more of 
the phthalate diesters is unlikely. The measured levels for down-
stream phthalate metabolites [mono-(2-ethyl-5-hydroxyhexyl) 
phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate, 
mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-
(3-carboxypropyl) phthalate, mono(hydroxyisononyl) phthalate, 
mono-oxoisononyl phthalate, mono(carboxyisooctyl) phthalate 
(MCiOP)] were quantitative, as conversion to these metabolites 
can occur only in vivo.
Whole blood glucose levels were measured using a standard 
glucose oxidase-based assay. Capillary blood glucose measure-
ments were made using an Abbott Freestyle Mini (Abbott 
Diagnostics, Maidenhead, UK). Fasting and stimulated insulin 
and C-peptide levels were measured by enzyme-linked immuno-
sorbent assay using commercial kits (DSL, London, UK).
calculations
Analyses of associations with parameters of blood glucose 
homeostasis included only those chemicals measured above the 
LOD in >60% of samples. Concentrations below the LOD were 
assigned a value equal to LOD/2 if the data were highly skewed 
or LOD/√2 if not (26). These substituted data were then used for 
all subsequent analyses. Concentrations were log-transformed to 
correct for non-normal distributions with positive skew. For cat-
egorical analyses, subjects were categorised into quartiles using 
the 25th, 50th, and 75th percentiles of the subcohort (n = 232), 
with the first quartile used as the referent category.
For the purposes of diagnosing GDM and estimating β-cell 
function and insulin resistance, venous plasma glucose levels 
were estimated by multiplying venous whole blood glucose 
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levels, where available, by 1.08, assuming a haematocrit of 
31.5% (27, 28). For the 176 women who completed an OGTT 
prior to May 2007 and, therefore, did not have a 120-min 
venous whole blood glucose level measured, 120-min venous 
plasma glucose level was estimated using the equation venous 
plasma glucose  =  1.035  ×  capillary blood glucose—0.891, 
which was derived from a linear regression model assessing 
the ability of 60-min capillary blood glucose to predict 60-min 
venous plasma glucose using data from the entire CBGS 
cohort [R2 = 0.790, F(1,768) = 2,889.3, p = 2 × 10−262]. A linear 
regression model assessing the ability of fasting capillary blood 
glucose to predict fasting venous plasma glucose gave a differ-
ent result: venous plasma glucose =  0.826 ×  capillary blood 
glucose + 0.996 [R2 = 0.511, F(1,759) = 792.6, p = 6 × 10−120]; 
however, we justified using the first equation to estimate the 
missing 120-min venous plasma glucose levels as across the 
entire CBGS cohort the mean 60-min venous plasma glucose 
(7.4 mmol/l) was closer to the mean 120-min venous plasma 
glucose (6.9  mmol/l) than the mean fasting venous plasma 
glucose (4.7 mmol/l) The updated homeostasis model assess-
ment (HOMA2) was used to estimate steady-state β-cell func-
tion (HOMA2-B, using fasting C-peptide and plasma glucose 
levels) and insulin resistance (HOMA2-IR, using fasting 
insulin and plasma glucose levels) (29); software for calculat-
ing these values is available online (https://www.dtu.ox.ac.uk/
homacalculator/). To estimate insulin secretion independent of 
insulin sensitivity, we calculated the disposition index as the 
60-min insulinogenic index [(insulin 60 −  insulin 0)/(venous 
glucose 60 − venous glucose 0)] divided by HOMA2-IR (30). 
HOMA2-B, HOMA2-IR, and disposition index were log-
transformed to normalise distributions.
Diagnosis of gDM
For primary analyses, women were diagnosed with GDM if they 
met one or more of the following criteria: fasting plasma glucose 
≥5.1 mmol/l, 60-min plasma glucose ≥10.0 mmol/l, or 120-min 
plasma glucose ≥8.5 mmol/l (31, 32). For sensitivity analyses, the 
following criteria were used: fasting plasma glucose ≥7.0 mmol/l 
or 120-min plasma glucose ≥7.8 mmol/l (33).
neonatal examinations
Newborns were examined by research nurses, as far as possible in 
the first 2 weeks of life, either in hospital or at home visits. They 
were then re-examined during clinic visits at 3, 12, and 24 months 
of age. Birth weight as measured at delivery by midwives was 
taken from health records. Cryptorchidism was defined as one or 
more testes not present in the inferior half of the scrotum for at 
least a few moments after manipulation.
ethical approval
The study was approved by Cambridge Local Research Ethics 
Committee and adhered to the Declaration of Helsinki.
statistical analyses
Distribution percentiles of phthalate and phenol concentrations 
were calculated for women with and without GDM, and differ-
ences in patient characteristics were assessed using the t-test and 
Mann–Whitney U-test for continuous variables, and chi-square 
test for categorical variables.
Logistic regression was used to model the odds of GDM in 
relation to serum phthalate/phenol concentrations, adjusting 
for covariates of interest. Continuous relationships between 
phthalate/phenol levels and HOMA2-B, HOMA2-IR, fasting and 
120-min plasma glucose, and disposition index were individually 
assessed using multiple linear regression, adjusting for covariates 
of interest. We restricted these latter analyses to women who did 
not have GDM, because in women with GDM glucose toxicity 
per  se may cause insulin resistance and β-cell dysfunction (8). 
Outliers (data points with standardised residuals >3SDs) were 
removed in all regressions (typically 0–2 cases per regression). 
Tests of heterogeneity (phet) and linear trend (ptrend) in outcome 
value across serum phthalate/phenol concentration quartiles 
were performed. Because numerous chemicals were significantly 
correlated and several have been previously associated with 
dysglycaemia (7–11, 15–17), regression analyses were conducted 
separately for each chemical, and we did not correct for multiple 
testing.
The following potential confounders were chosen a priori as 
covariates in the multivariable analyses because of their known 
biological relevance to the outcomes of interest (12): age, pre-
pregnancy BMI (log-transformed to normalise the distribution), 
IMD (log-transformed), and parity (nulliparous vs. para 1 vs. 
para 2 or greater). We did not use ethnicity or smoking status 
in our regressions, because very few women were of non-white 
ethnicity (4/151, 2.6%) or were smokers (5/232, 2.2%), and data 
on ethnicity were missing for 81/232 (34.9%) women.
In view of the nature of our subcohort (case-control study of 
cryptorchidism) and a possible association between GDM and 
congenital cryptorchidism (34), we additionally used logistic 
regression to model the odds of GDM in relation to cryptorchidism 
at birth, and multiple linear regression to assess the relationship 
between cryptorchidism and HOMA2-B, HOMA2-IR, fasting/
stimulated plasma glucose, and disposition index in women who 
did not have GDM, adjusting all analyses for the above covariates 
as well as prematurity (gestation <37 vs. ≥37 weeks) and small for 
gestational age (birth weight SD score <−1.5 vs. ≥−1.5), which 
are both risk factors for cryptorchidism (34). Finally, we used 
logistic regression to remodel the odds of GDM in relation to 
serum phthalate/phenol concentrations after excluding mothers 
of sons with congenital cryptorchidism.
All p-values were two-sided and p <  0.05 was considered 
statistically significant. Data were analysed using SPSS, version 
22.0 (IBM Corporation, New York, NY, USA).
resUlTs
232 women participated in the study, of whom 47 (20.3%) met 
one or more criteria for GDM (Table 2). Of these, 34 (72.3%) had 
an abnormal fasting plasma glucose, 18 (38.3%) had an abnor-
mal 60-min glucose, and 14 (29.8%) had an abnormal 120-min 
glucose.
Six phthalate metabolites [MEP, MiBP, mono-n-butyl phtha-
late (MnBP), MEHP, MECPP, MCiOP] and three phenols (BPA, 
triclosan, BP-3) were detectable in >60% of samples (Table  1; 
Table 3 | Adjusted odd ratios and 95% CIs for incident gestational diabetes 
mellitus in relation to log-transformed serum chemical concentrations.
log-transformed serum chemical 
concentration
adjusted modela
Or (95% ci) p-Value
Monoethyl phthalate 0.81 (0.39–1.70) 0.58
Monoisobutyl phthalate 1.48 (0.51–4.34) 0.47
Mono-n-butyl phthalate 1.55 (0.45–5.33) 0.49
Mono-(2-ethylhexyl) phthalate 0.93 (0.66–1.31) 0.67
Mono-(2-ethyl-5-carboxypentyl) phthalate 0.75 (0.27–2.06) 0.57
Mono(carboxyisooctyl) phthalate 1.12 (0.47–2.66) 0.81
Bisphenol A 1.16 (0.48–2.78) 0.74
Triclosan 0.54 (0.34–0.86) 0.010*
Benzophenone-3 0.80 (0.44–1.44) 0.45
aAdjusted for age, pre-pregnancy body mass index (log-transformed),  
IMD (log-transformed), and parity; n = 197 for phthalates, n = 193 for phenols.
*p < 0.05.
Table 2 | Characteristics of the study population.
characteristicsa Women with 
gestational  
diabetes mellitus 
(gDM) (n = 47)
Women  
without  
gDM  
(n = 185)
p-Value  
for gDM  
vs. no 
gDMb
Age (years) 33.1 ± 4.4 33.7 ± 3.8 0.30
Pre-pregnancy body  
mass index (kg/m2)
25.4 ± 5.1 23.7 ± 3.7 0.051
ethnicityc
White 28 (100%) 119 (96.7%) 0.75
Other 0 (0%) 4 (3.3%)
current smoker
No 46 (97.9%) 181 (97.8%) 0.99
Yes 1 (2.1%) 4 (2.2%)
Parity
0 21 (44.7%) 87 (47.3%) 0.91
1 20 (42.6%) 72 (39.1%)
≥2 6 (12.8%) 25 (13.6%)
Index of multiple  
deprivation (U)
9.43 ± 3.48 9.35 ± 4.27 0.90
Fasting plasma  
glucose (mmol/l)
5.5 ± 0.9 4.5 ± 0.3 4 × 10−9*
60-min plasma  
glucose (mmol/l)
9.5 ± 2.0 7.1 ± 1.5 1 × 10−10*
120-min plasma  
glucose (mmol/l)
7.6 ± 1.7 5.9 ± 1.0 3 × 10−8*
HOMA2-B (%) 113.7 (94.7–125.9) 120.0 (106.0–146.1) 0.07
HOMA2-IR (U) 1.35 (0.96–1.68) 0.82 (0.67–1.08) 2 × 10−6*
Disposition index  
(mmol/pmol.U)
119.7 (59.6–160.2) 152.7 (112.0–284.9) 0.001*
infant with congenital  
cryptorchidism
No 43 (91.5%) 173 (93.5%) 0.87
Yes 4 (8.5%) 12 (6.5%)
aMean ± SD or median (IQR) for continuous variables, n (%) for categorical variables.
bMann–Whitney U-test for HOMA2-B, HOMA2-IR, and disposition index; t-test for other 
continuous variables; chi-square test for categorical variables (with continuity correction 
for 2 × 2 tables).
cData on ethnicity are missing for n = 81 women.
*p < 0.05.
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Table S1 in Supplementary Material). Some phthalate metabolites 
were strongly or moderately intercorrelated (MnBP and MiBP, 
rho =  0.838, p =  2 ×  10−62; MECPP and MCiOP, rho =  0.357, 
p =  2 ×  10−8), and several of the other chemicals were weakly 
correlated (Table S1 in Supplementary Material).
In continuous models, of these nine chemicals, only triclosan 
was associated with incident GDM [adjusted OR (aOR) per log 
increase in concentration 0.54, 95% CI 0.34–0.86, p = 0.010] 
(Table  3). We conducted a categorical analysis to look for 
threshold and non-linear effects (Table 4). In accordance with 
the continuous analysis, this demonstrated lower odds of GDM 
in the second (aOR 0.25, 95% CI 0.07–0.86, p = 0.028), third 
(aOR 0.12, 95% CI 0.03–0.55, p = 0.007), and fourth (aOR 0.35, 
95% CI 0.12–0.98, p = 0.046) quartiles for triclosan, compared 
to the first quartile (phet = 0.009, ptrend = 0.022). Inspection of 
the data did not reveal evidence for a threshold or non-linear 
relationship. Conversely, women with MiBP levels in the sec-
ond (aOR 5.69, 95% CI 1.56–20.73, p =  0.008) and fourth 
(aOR 4.89, 95% CI 1.32–18.14, p =  0.018) quartiles, but not 
in the third quartile, had higher odds of GDM (phet =  0.001, 
ptrend = 0.41).
To explore the robustness of our results, and in view of the 
high incidence of GDM in our sample compared to previous 
studies (2), we repeated our analyses for MiBP and triclosan using 
the more stringent 1999 World Health Organization (WHO) 
criteria for GDM, i.e., fasting plasma glucose ≥7.0  mmol/l or 
120-min plasma glucose ≥7.8 mmol/l (33). Using these criteria, 
the incidence of GDM was 27/232 (11.6%). The inverse associa-
tion between incident GDM and triclosan persisted in both the 
continuous analysis (aOR 0.25, 95% CI 0.09–0.65, p = 0.005) and 
the categorical analysis (phet = 0.28, ptrend = 0.006). However, there 
was no significant association between MiBP levels and incident 
GDM (data not shown).
Among women without GDM at 28  weeks of gestation 
(n = 185), MEHP was positively associated with 120-min plasma 
glucose (adjusted β 0.268, p = 0.0002), explaining 6.9% of the vari-
ation in 120-min glucose (Table S2 in Supplementary Material). 
MCiOP was also positively associated with 120-min glucose 
(adjusted β 0.183, p = 0.010), explaining 3.4% of the variation in 
120-min glucose. Other phthalate metabolites (including MiBP) 
and all phenols were not significantly associated with fasting/
stimulated glucose levels, HOMA2-B, HOMA2-IR, or disposi-
tion index (Table S2 in Supplementary Material).
Experimental studies suggest that MEHP, the primary metabo-
lite of DEHP, may have greater endocrine disrupting activity that is 
secondary metabolites, such as MECPP (35). We, therefore, tested 
the associations between the molar ratio of MEHP to MECPP 
(MEHP/MECPP ratio), as an inverse marker of detoxification 
capability (23), and parameters of blood glucose homeostasis in 
women without GDM. The MEHP/MECPP ratio was positively 
associated with 120-min plasma glucose (adjusted β 0.280, 
p = 0.00008), explaining 7.6% of the variation in 120-min glucose, 
but not any other indices of glucose homeostasis.
We hypothesised that the lack of association of MEHP and 
MCiOP with GDM, despite their positive associations with 120-min 
plasma glucose, may reflect the relatively small proportion of 
cases in our sample with abnormal 120-min glucose levels, 
owing to the use of a higher diagnostic threshold (≥8.5 mmol/l) 
(31, 32) than has featured in previous GDM guidelines (e.g., 
≥7.8  mmol/l) (33). We, therefore, repeated our GDM analyses 
for MEHP and MCiOP using the 1999 WHO criteria (33). 
Table 4 | Adjusted odd ratios and 95% CIs of incident gestational diabetes mellitus (GDM) by category of concentrations of the different chemicals.
chemical Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-Value for  
heterogeneity
p-Value for 
linear trend
Monoethyl phthalate
Incidence of GDM (%) 10/58 (17.2%) 14/58 (24.1%) 10/58 (17.2%) 13/58 (22.4%) 0.45 0.87
Adjusted OR (95% CI)a Referent 1.65 (0.60–4.56) 0.67 (0.21–2.07) 1.19 (0.42–3.37)
Monoisobutyl phthalate
Incidence of GDM (%) 9/58 (15.5%) 17/58 (29.3%) 6/58 (10.3%) 15/58 (25.9%) 0.001* 0.41
Adjusted OR (95% CI)a Referent 5.69 (1.56–20.73)* 0.37 (0.06–2.26) 4.89 (1.32–18.14)*
Mono-n-butyl phthalate
Incidence of GDM (%) 13/66 (19.7%) 12/50 (24.0%) 9/58 (15.5%) 13/58 (22.4%) 0.26 0.81
Adjusted OR (95% CI)a Referent 1.17 (0.40–3.41) 0.43 (0.13–1.44) 1.42 (0.52–3.88)
Mono-(2-ethylhexyl) phthalate
Incidence of GDM (%) 17/84 (20.2%) 8/32 (25.0%) 11/58 (19.0%) 11/58 (19.0%) 0.53 0.77
Adjusted OR (95% CI)a Referent 2.14 (0.72–6.35) 1.14 (0.42–3.09) 1.03 (0.38–2.79)
Mono-(2-ethyl-5-carboxypentyl) phthalate
Incidence of GDM (%) 12/58 (20.7%) 11/58 (19.0%) 9/58 (15.5%) 15/58 (25.9%) 0.29 0.78
Adjusted OR (95% CI)a Referent 0.61 (0.20–1.81) 0.42 (0.13–1.36) 1.19 (0.44–3.17)
Mono(carboxyisooctyl) phthalate
Incidence of GDM (%) 9/58 (15.5%) 13/58 (22.4%) 11/58 (19.0%) 14/58 (24.1%) 0.87 0.89
Adjusted OR (95% CI)a Referent 1.54 (0.53–4.52) 1.18 (0.38–3.67) 1.39 (0.47–4.14)
Bisphenol A
Incidence of GDM (%) 11/57 (19.3%) 15/57 (26.3%) 13/57 (22.8%) 7/57 (12.3%) 0.07 0.24
Adjusted OR (95% CI)a Referent 2.58 (0.84–7.94) 1.04 (0.31–3.53) 0.56 (0.14–2.28)
Triclosan
Incidence of GDM (%) 19/70 (27.1%) 8/44 (18.2%) 8/57 (14.0%) 11/57 (19.3%) 0.009* 0.022*
Adjusted OR (95% CI)a Referent 0.25 (0.07–0.86)* 0.12 (0.03–0.55)* 0.35 (0.12–0.98)*
Benzophenone-3
Incidence of GDM (%) 10/68 (14.7%) 9/46 (19.6%) 16/57 (28.1%) 11/57 (19.3%) 0.83 0.95
Adjusted OR (95% CI)a Referent 1.09 (0.38–3.14) 1.40 (0.52–3.77) 0.86 (0.29–2.51)
aAdjusted for age, pre-pregnancy body mass index (log-transformed), IMD (log-transformed), and parity; n = 197 for phthalates, n = 193 for phenols.
*p < 0.05.
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In continuous models, neither MEHP (aOR per log increase in 
concentration 1.57, 95% CI 0.88–2.78, p =  0.12) nor MCiOP 
(aOR per log increase in concentration 3.02, 95% CI 0.81–11.26, 
p = 0.10) was associated with incident GDM; and MCiOP was 
not associated with GDM in the categorical analysis (phet = 0.87, 
ptrend = 0.46). However, women with MEHP levels in the second 
(aOR 25.82, 95% CI 1.79–372.52, p =  0.017) and fourth (aOR 
23.22, 95% CI 1.68–320.03, p = 0.019) quartiles, but not in the 
third quartile (aOR 8.09, 95% CI 0.59–111.44, p =  0.12), had 
significantly increased odds of GDM (phet = 0.08, ptrend = 0.041).
Of the 232 male infants born to the women in our study, 16 
(6.9%) had cryptorchidism at birth (Table 2). An additional 16 
(6.9%) infant had cryptorchidism at 3, 12, or 24 months of age, 
but not at birth. Congenital cryptorchidism was not associated 
with maternal GDM (aOR 1.46, 95% CI 0.39–5.50, p = 0.58) or 
fasting/stimulated glucose levels, HOMA2-B, HOMA2-IR, or 
disposition index (data not shown). When we remodelled the of 
odds of GDM in relation to serum phthalate/phenol concentra-
tions in the 216 mothers whose sons did not have cryptorchidism 
at birth, our results were not substantially different from the 
primary analyses: triclosan was associated with incident GDM in 
both the continuous analysis (aOR per log increase in concentra-
tion 0.48, 95% CI 0.28–0.82, p = 0.007) and categorical analysis 
(phet = 0.027, ptrend = 0.019), and women with MiBP levels in the 
second (aOR 7.33, 95% CI 1.71–31.34, p =  0.007) and fourth 
(aOR 5.31, 95% CI 1.25–22.53, p = 0.024) quartiles, but not in the 
third quartile, had higher odds of GDM (phet = 0.002, ptrend = 0.39) 
(other data not shown).
DiscUssiOn
Using a prospective cohort design, we examined the associations 
between serum levels of phthalate metabolites, BPA, triclosan, 
and BP-3 measured at 10–17 weeks of gestation with GDM and 
indices of blood glucose homeostasis at 28 weeks of gestation. 
We observed a moderate inverse association between triclosan 
levels and GDM, and an apparent non-linear association 
between MiBP and GDM. We also demonstrated that MEHP, 
MCiOP, and the MEHP/MECPP ratio were positively associated 
with 120-min glucose levels but no other markers of glucose 
homeostasis in women without GDM. Sensitivity analyses using 
the 1999 WHO criteria for GDM suggested an additional non-
linear association between MEHP levels and GDM. We did not 
find any significant associations for BPA.
Triclosan was inversely associated with incident GDM, with 
no evidence of a threshold or non-linear relationship. This 
unexpected association persisted in a sensitivity analysis using 
alternative GDM diagnostic criteria and a further analysis in 
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which mothers whose sons had congenital cryptorchidism were 
excluded. There were no concomitant associations between 
triclosan and markers of glucose homeostasis in non-diabetic 
women. The only relevant experimental study of triclosan to 
date showed that administration to pregnant mice at 8 mg/kg/
day—several thousand times the average human intake (36)— 
resulted in IGT with increased insulin resistance and reduced 
β-cell function at gestational day 17, although this effect was 
not seen at lower doses (1–4  mg/kg/day) (37). An epidemio-
logical study found no associations between urinary triclosan 
levels and patient-reported diabetes, fasting glucose, or fasting 
insulin in 1,455 non-pregnant adults (20). However, a reduction 
in GDM incidence could, at least in part, explain a reported 
inverse association between maternal triclosan levels and fetal 
growth in the third trimester (38). Triclosan is a broad-spectrum 
antimicrobial agent commonly used in personal care products 
such as soaps, toothpastes, and deodorants (although in 2016, 
it was banned from hand/body washes by the US Food and 
Drug Administration and the European Commission) (39). The 
mechanism for its apparent protective effect against GDM is 
unknown, but possibilities might include a reduction in systemic 
inflammation, and consequently insulin resistance, through its 
antimicrobial and/or anti-inflammatory actions (40, 41), or an 
increase in catabolism and weight loss through mitochondrial 
uncoupling (41). Alternatively, the strong inverse association 
observed between triclosan and GDM risk may reflect residual 
confounding due to unmeasured maternal factors: for example, 
triclosan levels may be indicative of health-related behaviours 
such as better personal care and greater health consciousness, 
which may in turn be protective against GDM (2).
Of the phthalate metabolites, only MiBP was associated 
with incident GDM in our primary analyses, although in a 
non-linear manner, with increased odds in the second and top 
quartiles only. Non-monotonic dose–response relationships 
are well described in the EDC literature, including for certain 
phthalates (42); however, the majority of such relationships are 
biphasic. We could not find any historical data to support a 
possible mechanistic explanation for the M-shaped relationship 
observed for MiBP. Furthermore, MiBP was not associated with 
any other markers of glucose homeostasis in our study. We, 
therefore, conclude that our data do not support a true effect 
of MiBP on GDM.
Mono-(2-ethylhexyl) phthalate and MCiOP were positively 
associated with 120-min plasma glucose. These findings are 
consistent with the in vitro actions of phthalates (4) and rodent 
studies of DEHP (6). Two epidemiological studies of summed 
DEHP metabolites (including MEHP) have demonstrated 
associations with T2DM (7, 9)—although other studies assess-
ing MEHP in isolation have not found associations with T2DM 
or 120-min glucose (7, 8), and none have assessed glycaemia 
in relation to MCiOP. We also found that the MEHP/MECPP 
ratio was positively associated with 120-min glucose, consistent 
with MEHP having greater endocrine disrupting activity than 
its secondary metabolites (35). The lack of association of these 
phthalate metabolites with fasting glucose, HOMA2-B, and 
HOMA2-IR could be due to a greater effect on stimulated, rather 
than baseline, insulin secretion, although we did not detect an 
association with 60-min insulin secretion (disposition index), 
either. We hypothesised that the lack of association with GDM 
in our primary analysis reflected the relatively small number of 
cases with abnormal 120-min glucose levels, and in a sensitivity 
analysis using a lower diagnostic threshold (≥7.8 mmol/l rather 
than ≥8.5 mmol/l), we found some evidence for an association 
between MEHP and incident GDM (significantly increased odds 
of GDM in the second and top quartiles only). It is possible that 
this association might be stronger in a population with higher 
MEHP levels, resulting in a greater incidence of abnormal 120-
min glucose levels. In support of this, an association between 
summed DEHP metabolites and incident T2DM was reported 
in a cohort of women with high urinary concentrations (median 
302–325 nmol/l) but not in a cohort with lower concentrations 
(median 230–278 nmol/l) (9).
Our phthalate results do not corroborate with three other 
recent prospective studies of GDM, which variously reported 
inverse associations of MiBP and MBzP with 60-min glucose 
(10), a positive association of MEP with IGT but an inverse 
association of DEHP metabolites with IGT (11), and no asso-
ciations of any phthalates with IGT/GDM (12). Furthermore, 
we did not find any associations between BPA and incident 
GDM or markers of glucose homeostasis, in contrast to vari-
ous epidemiological studies of BPA and T2DM (9, 15, 17), and 
one previous study (18), but not two others (12, 19), of BPA 
and gestational glycaemia. These discrepancies may reflect dif-
ferences in methodology, such as the matrix of measurement 
(urine vs. serum) (43), glucose load used (50 vs. 75 g), or gesta-
tion at phthalate/BPA measurement (first vs. second trimester) 
(18); or differences between the study populations and our own: 
for example, the three cohorts in which relationships between 
phthalate levels and GDM were previously assessed had higher 
prevalences of overweight/obesity (>50, 45.4, and 37.3 vs. 
33.8%) and non-white ethnicity (47.2, 41.1, and 15.5 vs. 1.7%) 
than our own; and our cohort did not include mothers of female 
infants.
The prevalence of GDM in our subcohort (20.3%) was several-
fold higher than the reported prevalence for England and Wales 
(~3.5%) (1). This may reflect our use of the new international 
criteria for GDM (31, 32), which differ from those used by most 
previous population studies (2), and from those currently advo-
cated in England and Wales (1); indeed, using older criteria (33), 
the prevalence in our subcohort was markedly lower (11.6%), 
although still higher than reported by most previous European 
population studies (0.6–22.3%) (2). Additionally, the women in 
our study may not be truly representative of the entire CBGS 
cohort. For example, several studies have suggested that women 
carrying a male fetus have an increased risk of GDM (44–46), 
and some authors have reported an association between GDM 
and congenital cryptorchidism (34), although we and others have 
found no such link (47).
We did not have data for all possible confounders: for example, 
education, income, activity levels, diet, subfertility, family history 
of diabetes, and other EDCs (12, 18). This may have led to overes-
timation of effect sizes, as may have any antagonistic interactions 
between EDCs. Conversely, we cannot rule out over-adjustment 
in our analyses: for example, if an EDC had independent effects 
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on both adiposity and glucose intolerance, then, correction for 
BMI would have led to an underestimation of its effect on GDM.
Serum phthalate metabolite levels in our study were of a 
similar order of magnitude to those reported in other cohorts 
of pregnant or postpartum women (48, 49). Serum triclosan 
levels were ~10-fold to 20-fold lower than reported in Australian 
women of childbearing age (50), but of a similar range to those in 
US adults and children (51, 52).
Strengths of our study include its prospective design; use 
of laboratory criteria to diagnose GDM; sample collection and 
storage in glass tubes (to avoid phthalate/BPA contamination); 
use of a highly sensitive technique for measuring the chemicals; 
and our ability to account for a number of potential confounding 
variables. This is also the first study to examine the association 
between phthalate metabolites and phenols and markers of insu-
lin resistance and β-cell function in pregnant women.
Our study has several limitations. First, the sample size 
was relatively small, which will have limited precision and 
statistical power, although it was larger than two of the five 
previously published studies of phthalates/BPA and GDM 
(10, 19). Second, our use of the 60-min disposition index 
to assess insulin secretion may have weakened associations 
between chemical levels and first-phase insulin secretion 
because the 60-min insulinogenic index is not as robust a 
measure of β-cell function as the 30-min insulinogenic index 
(53). Third, measurement of serum levels of the chemicals may 
have resulted in exposure misclassification: phthalates (24), 
BPA (54), and triclosan (55) all have short biological half-lives 
(<24 h), meaning that serum measurements may reflect recent 
brief exposures rather than the subjects’ daily habits; and the 
levels of these chemicals can be several orders of magnitude 
lower in serum than urine (24, 43), increasing the possibil-
ity that external/iatrogenic contamination has obscured true 
exposures. However, we believe that our positive findings 
are valid, for several reasons: we took steps to avoid external 
contamination of serum; MCiOP and MECPP are downstream 
phthalate metabolites, which are not known to form as a 
result of external contamination (43); and it is most likely that 
exposure misclassification would be non-differential, which 
would attenuate, rather than enhance, any relationships found. 
The final study limitation was that we examined effects of the 
phthalate metabolites and phenols individually, with no allow-
ance for mixture effects or corrections for multiple testing. 
However, we feel that the latter is justified by the previously 
demonstrated associations with glucose metabolism for many 
of the chemicals (7–11, 15–17); and indeed most significant 
p values were ≤ 0.01, making a type-1 error unlikely.
In conclusion, our study provides a novel and interesting 
demonstration of inverse association between maternal serum 
triclosan levels at 10–17 weeks of gestation and incident GDM, 
in addition to biologically plausible associations between 
MEHP, MCiOP, and the MEHP/MECPP ratio and stimulated 
blood glucose levels. However, these findings need to be 
confirmed by further carefully designed prospective studies in 
other settings, that use a variety of specimen types (including 
urine) and assess exposure levels at multiple time points. More 
evidence is required before specific recommendations can be 
made with regards to clinical practice in diabetes or public 
health policy.
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